ZA202106551B - Anti-bag2 antibody and methods of treating cancer - Google Patents

Anti-bag2 antibody and methods of treating cancer

Info

Publication number
ZA202106551B
ZA202106551B ZA2021/06551A ZA202106551A ZA202106551B ZA 202106551 B ZA202106551 B ZA 202106551B ZA 2021/06551 A ZA2021/06551 A ZA 2021/06551A ZA 202106551 A ZA202106551 A ZA 202106551A ZA 202106551 B ZA202106551 B ZA 202106551B
Authority
ZA
South Africa
Prior art keywords
antibody
treating cancer
bag2
methods
fragment
Prior art date
Application number
ZA2021/06551A
Other languages
English (en)
Inventor
Seong Jin Kim
Dong Woo Kang
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190016347A external-priority patent/KR102172541B1/ko
Priority claimed from KR1020190016359A external-priority patent/KR102241558B1/ko
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of ZA202106551B publication Critical patent/ZA202106551B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2021/06551A 2019-02-12 2021-09-07 Anti-bag2 antibody and methods of treating cancer ZA202106551B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020190016347A KR102172541B1 (ko) 2019-02-12 2019-02-12 Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법
KR1020190016359A KR102241558B1 (ko) 2019-02-12 2019-02-12 Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
PCT/IB2020/051136 WO2020165794A1 (en) 2019-02-12 2020-02-12 Anti-bag2 antibody and methods of treating cancer

Publications (1)

Publication Number Publication Date
ZA202106551B true ZA202106551B (en) 2024-12-18

Family

ID=72044199

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/06551A ZA202106551B (en) 2019-02-12 2021-09-07 Anti-bag2 antibody and methods of treating cancer

Country Status (11)

Country Link
US (2) US12122822B2 (https=)
EP (2) EP3938788A4 (https=)
JP (4) JP7706154B2 (https=)
CN (2) CN114269779B (https=)
AU (1) AU2020222326B2 (https=)
BR (1) BR112021015940A2 (https=)
CA (1) CA3129748A1 (https=)
MX (1) MX2021009690A (https=)
SG (1) SG11202108140SA (https=)
WO (2) WO2020165797A1 (https=)
ZA (1) ZA202106551B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560537B2 (en) 2002-09-30 2009-07-14 Ludwig Institute For Cancer Research Human sarcoma-associated antigens
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
JP2008518629A (ja) 2004-11-08 2008-06-05 シェーリング コーポレイション Ｍｄｌ−１の腫瘍との関連およびその方法
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
EP2142670A1 (en) * 2007-04-05 2010-01-13 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
JP6637290B2 (ja) * 2015-11-05 2020-01-29 武 永安 Ｃｋ１９に特異的なモノクローナル抗体およびこれを産生するハイブリドーマ、癌の検出キット、癌の検出方法および癌の転移の判定方法
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
KR102039624B1 (ko) * 2017-03-03 2019-11-01 재단법인 차세대융합기술연구원 BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Also Published As

Publication number Publication date
JP2022521706A (ja) 2022-04-12
AU2020222326B2 (en) 2026-03-19
JP7747268B2 (ja) 2025-10-01
JP2025071090A (ja) 2025-05-02
CN114269779B (zh) 2025-05-09
EP3938788A4 (en) 2023-01-04
WO2020165794A1 (en) 2020-08-20
MX2021009690A (es) 2021-10-01
JP2022525843A (ja) 2022-05-20
CA3129748A1 (en) 2020-08-20
JP7706154B2 (ja) 2025-07-11
CN114269779A (zh) 2022-04-01
EP3924382A4 (en) 2023-01-04
BR112021015940A2 (pt) 2021-10-05
CN114761803B (zh) 2025-09-05
JP2025071822A (ja) 2025-05-08
US20230183324A1 (en) 2023-06-15
CN114761803A (zh) 2022-07-15
EP3938788A1 (en) 2022-01-19
US20230194534A1 (en) 2023-06-22
US12583915B2 (en) 2026-03-24
WO2020165797A1 (en) 2020-08-20
EP3924382A1 (en) 2021-12-22
AU2020222326A1 (en) 2021-08-19
US12122822B2 (en) 2024-10-22
SG11202108140SA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
PH12019502857A1 (en) Il-1 beta binding antibodies for use in treating cancer
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
EP4653463A3 (en) Antibodies
EA202190088A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1
EP4644427A3 (en) Manabodies and methods of using
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
PH12022552741A1 (en) Anti-ox40 antibody and uses thereof
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
ZA202205288B (en) Humanized antibody and method for using the same
MX2024014232A (es) Anticuerpo anti-b7h3 y usos del mismo
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MY208387A (en) Antibodies specifically recognizing pseudomonas pcrv and uses thereof
ZA202106551B (en) Anti-bag2 antibody and methods of treating cancer